GLP-1 receptor agonists, the drug class behind semaglutide, are now showing biopsy-confirmed benefits in MASH, the inflammatory form of fatty liver disease, with a 72-week trial reporting resolution in 62.9% of participants on semaglutide versus 34.3% on placebo.
News-Medical reported on the accumulated evidence behind those numbers, drawing on recent meta-analyses of randomized controlled trials published in journals including Liver International and Pharmaceutics. The stakes are high: metabolic dysfunction-associated steatotic liver disease, or MASLD, affects up to 38% of the global population and is projected to reach 55% by 2040, according to Tavaglione and Loomba.
MASH — formerly called NASH — is the stage where liver fat is joined by inflammation and hepatocellular ballooning, a form of liver cell swelling and injury. Left to progress, fibrosis can advance to cirrhosis, liver failure, or hepatocellular carcinoma. Cardiovascular disease, News-Medical noted, contributes substantially to death and illness in these patients, which is why treatments that address both metabolism and liver pathology matter.
Regulators have already moved. In August 2025, the US Food and Drug Administration granted accelerated approval to Wegovy (semaglutide) for adults with noncirrhotic MASH and moderate-to-advanced fibrosis (stages F2–F3), to be used alongside a reduced-calorie diet and increased physical activity — with continued approval contingent on confirmed clinical benefit, per the FDA’s 2026 prescribing information.
Drugs Reverse Inflammation and Reduce Scarring in Moderate Cases
- These drugs appear to reverse liver inflammation and, in some patients, reduce scarring — but the evidence is strongest for people with moderate scarring who do not yet have cirrhosis.
- Liver enzyme improvements on blood tests do not prove the liver is healing; biopsy-confirmed changes are the real benchmark.
- Side effects are real and mostly digestive: nausea, vomiting, diarrhea, and constipation, often managed by slowly increasing the dose.
Trials Show Weight Loss Drives MASH Improvement
GLP-1 receptor agonists mimic a gut hormone. Their mechanism of action — the way a drug produces its effect — is threefold: they increase glucose-dependent insulin secretion, promote satiety, and slow gastric emptying.
Weight loss is the primary route by which they improve MASH, News-Medical reported, though experimental work suggests anti-inflammatory and antifibrotic pathways may contribute, partly independent of weight loss. Whether GLP-1 receptors on human hepatocytes, the liver’s main cells, mediate a direct benefit remains uncertain.
The headline data come from the 72-week ESSENCE analysis, in participants with biopsy-confirmed MASH and stage F2 or F3 fibrosis — moderate and advanced scarring. Semaglutide 2.4 mg once weekly produced MASH resolution without worsening fibrosis in 62.9% of participants versus 34.3% on placebo. Fibrosis improved without worsening MASH in 36.8% versus 22.4%. Earlier analyses had lacked sufficient biopsy evidence for a fibrosis benefit; ESSENCE strengthened the case, particularly for semaglutide.
Recent meta-analyses of randomized controlled trials — including one in the Journal of the Canadian Association of Gastroenterology — support both histological endpoints regulators consider acceptable for accelerated approval in MASH clinical trials: resolution of MASH without fibrosis worsening, and at least one-stage fibrosis improvement without MASH worsening.
There is a hard limit to the optimism. A 48-week semaglutide trial in compensated MASH-related cirrhosis — cirrhosis without overt complications — did not show improved fibrosis or MASH resolution versus placebo. Benefits seen in noncirrhotic fibrosis cannot be extrapolated to cirrhosis, News-Medical reported.
Additional coverage from Medical Xpress, reporting on work published in Lancet Gastroenterology & Hepatology, carried the same caution alongside a note of persistence from researcher Loomba: “These findings strengthen the need to continue studying semaglutide and other metabolic therapies in advanced liver disease.”
Dual Agonists Show Larger Effects but Lack Head-To-Head Proof
Research is expanding past single-receptor drugs. These incretin-based therapies include GLP-1 receptor agonists alone as well as dual and triple combinations that add GIP and/or glucagon receptor activity. Some subgroup analyses suggest larger effects with dual agonists on body weight and hepatic outcomes, but these comparisons draw on different trials and few studies — they do not establish superiority, and head-to-head trials are needed, News-Medical reported.
Tavaglione and Loomba frame these incretin-based therapies as promising particularly for patients with coexisting obesity or type 2 diabetes, noting pleiotropic effects — actions in multiple organs — including cardiovascular and renal benefits.
What the Evidence Still Cannot Say
Three gaps matter most. First, the current evidence comes from phase 2 and phase 3 trials focused on histology-assessed hepatic endpoints, leaving longer-term clinical outcomes unresolved. Second, trials differ substantially in design, population, duration, and comparators, making direct comparisons difficult. Third, a 2026 meta-analysis found no statistically significant benefits in weight or fibrosis in the small subgroup of patients without type 2 diabetes.
References
- Mantovani, A., et al. (2025). A meta-analysis of randomized controlled trials finds that glucagon-like peptide-1 receptor agonists improve MASH and liver fibrosis. Liver International 45(9).
- Tornea, D. A., et al. (2026). A systematic review and meta-analysis examining how GLP-1 agonists affect patients with metabolic-associated steatotic liver disease. Pharmaceutics 18(1).
- Potter, K. J., et al. (2025). Effects of GLP-1 receptor agonist therapy on resolution of steatohepatitis in nonalcoholic fatty liver disease. Journal of the Canadian Association of Gastroenterology 8(2).
- Huang, X., et al. (2025). Gastrointestinal adverse events associated with GLP-1 receptor agonists in MASLD. Frontiers in Medicine 12.
- U.S. Food and Drug Administration. (2026). Wegovy prescribing information — MASH indication, accelerated approval.
This article is informational and does not constitute medical advice. Consult a qualified healthcare professional about diagnosis and treatment decisions.
Keep reading
- SISA 2025 Consensus: High Triglycerides Signal Residual Cardiovascular Risk Even With Controlled LDL
- Karl Lauterbach Warns Germany to Increase Measles Vaccination Rates
- SpaceX Share for Every Kid Needs a Charity and Treasury's Approval (daybreakwire.com)
- Lavoie: Demidov Could Rejoin Canadiens for Road Trip After Accelerated Rehab (world-today-journal.com)